If drug resistance occurs during the treatment of multiple myeloma patients, the treatment program should be changed according to the doctor’s recommendation, such as adding anthracycline drugs.
Currently, the treatment of multiple myeloma mainly relies on chemotherapy to alleviate the condition, and the commonly used first-line drugs are proteasome inhibitors (e.g. bortezomib, isazomib, etc.), immunomodulators (thalidomide, lenalidomide, pomalidomide, etc.), and glucocorticoid (dexamethasone), which are mainly used as the combination of chemotherapy, and the majority of the patients have good treatment effects.
If drug resistance occurs, it is necessary to replace the above chemotherapeutic drugs, or add anthracycline cytotoxic drugs, daltolizumab, etc. to improve the efficacy. Or CAR-T cell therapy followed by bridging hematopoietic stem cell transplantation.
Changing the treatment plan needs to be carried out under the evaluation and guidance of professional doctors. Patients must pay attention to rest during treatment, eat a light diet, adjust their mindset, and enhance their confidence in fighting the disease.